Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Estrogen or progesterone receptor positive stage IIIb/IV non-small cell lung cancer~* Eligible patients will have stable disease on erlotinib monotherapy at FDA- approved doses after a minimum duration of erlotinib therapy of 2 months~* 18 years or older~* ECOG Performance Status ≤2~* Adequate Organ Function Requirements~* Adequate coagulation function~* Postmenopausal status in female patients is required and is defined as no menstrual periods for 12 month or surgical menopause~* All patients must sign a written informed consent.~Exclusion Criteria:~* Pregnant or breast-feeding women will not be entered on this study~* Patients who are currently receiving another investigational drugs~* Patients who are currently receiving other anti-cancer agents.~* Hormone replacement therapy will not be allowed and have to be stopped 1 month prior to entry into the study~* Patients who have an uncontrolled infection.~* Patients receiving less than 100mg/day of erlotinib~* Patients with evidence of progression after 2 months of erlotinib monotherapy.~* Patients with a history of bleeding diathesis (i.e., disseminated intravascular coagulation \[DIC\], clotting factor deficiency) or long-term anticoagulant therapy (other than antiplatelet therapy).~* Patients with a history of hypersensitivity to active or inactive excipients of fulvestrant (i.e. castor oil or Mannitol).~* Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Single-arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).